Читать книгу Anti-Aging Therapeutics Volume XIII - A4M American Academy - Страница 25

The monitoring approach presented here is based on Dr. Bard’s 39-years experience in the field of diagnostic ultrasound, 15-years of imaging the prostate with power Doppler blood flows, and 6-years of performing 3-D PDS and comparing the results with high resolution MRI scans of the pelvis with special sequences formulated specifically for the prostate. Dr. Bard has diagnosed, observed, and shared in the treatment of some 5,900 patients. Through nutritional support, medical treatment when appropriate, and 3-D monitoring on a schedule dictated by each individual’s current situation, only 5 of these 5,900 men have died from their PCa in a 10-year time period. (This compares very favorably to the expected 239 deaths from PCa within 4 years of diagnosis, based on figures from the Health Professionals Follow-Up Study for men diagnosed with nonmetastatic PCa observed from 1990 to 2008.⁶)

ProActive Monitoring couples 3-D Doppler and MRI imaging at regular intervals with the B-Sit/AOX) nutritional support. The B-Sit/AOX approach was first developed out of Arthur Bartunek’s early work with coenzyme Q10 (CoQ10) and cofactors that improved Q10 outcomes, especially for cancers. The formulations and protocols used during proactive monitoring were further refined with feedback from the progressive 3-D Doppler monitoring of men with varying stages of PCa. During the 10-years of this process, improvements in imaging have allowed changes to be tracked more accurately, and to make appropriate nutritional adjustments based on this. In addition, the use of several nutritional items, notably curcumin and tocotrienols, have been independently developed for use with cancer and are reaching phase II and phase III clinical trials. These have been included in the protocol and are discussed here.